Importantly, there was a degree of consistency across trials: albumin use was repeatedly associated with reduced risk of AKI, hyponatremia, and paracentesis-induced circulatory dysfunction (PICD), reinforcing its role as a cornerstone in managing decompensated cirrhosis [21]. The gene discussed is ALB; the disease is acute kidney injury.